^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    LY96 (Lymphocyte Antigen 96)

    i
    Other names: LY96, Lymphocyte Antigen 96, MD-2,Protein MD-2, ESOP-1, Ly-96, MD2, Myeloid Differentiation Protein-2, ESOP1
    Associations

    News

    Trials
    3ms
    COVID-19 vaccination and miscarriage risk: RNA-seq and bioinformatics analysis at the maternal-foetal interface. (PubMed, J Glob Health)
    Gene set variation analysis suggested a positive influence of the vaccine on immune tolerance at MFI. This study indicates that the COVID-19 vaccine may exert nonnegative effects on the maternal-foetal immune micro-environment and is unlikely to increase the risk of miscarriage.
    Journal
    |
    LY96 (Lymphocyte Antigen 96)
    4ms
    Ly96-mediated activation of TGF-β1/Smad2/3 signaling in hepatocellular carcinoma and its potential for nanoparticle-based therapy. (PubMed, Acta Biochim Biophys Sin (Shanghai))
    For therapeutic applications, we develop a liposome-based nanoparticle system that delivers the LY96 inhibitor L6H21 to tumor cells and effectively suppresses HCC progression through a combination of in vivo and in vitro studies. Taken together, the current observations identify LY96 as a promising diagnostic indicator and a viable intervention for therapeutic modulation to improve HCC treatment.
    Journal
    |
    LY9 (Lymphocyte Antigen 9) • TGFB1 (Transforming Growth Factor Beta 1) • LY96 (Lymphocyte Antigen 96)
    6ms
    Inflammatory Gene Variants and Protein Levels: An Important Predictor of Prostate Cancer Development. (PubMed, J Environ Pathol Toxicol Oncol)
    In addition, IL-1β was associated with rs689466, LY96 with rs2228014, rs5743336 genotypes (P < 0.05). As a conclusion, the CCR3 gene rs4987053, COX-2 gene rs689466, and NOD1 gene rs5743336 variations were determined to be closely associated with prostate cancer risk.
    Journal
    |
    PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • CCR3 (C-C Motif Chemokine Receptor 3) • LY96 (Lymphocyte Antigen 96) • NOD1 (Nucleotide Binding Oligomerization Domain Containing 1)
    8ms
    Prognostic implications of high- OXPHOS macrophages in gastric cancer: a single-cell transcriptomics and tumor microenvironment communication study. (PubMed, Front Oncol)
    The high-OXPHOS-macrophage-related prognostic signature derived from scRNA-seq data provides valuable insights into GC patient stratification. NPC2, LY96, and TPP1, highly expressed in TAMs, were implicated in promoting tumor growth and immune escape, offering potential targets for novel therapeutic interventions.
    Journal
    |
    LY96 (Lymphocyte Antigen 96) • TPP1 (Tripeptidyl Peptidase 1)
    8ms
    Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers. (PubMed, Sci Rep)
    Drug sensitivity analysis revealed heightened sensitivity to cyclophosphamide, Sinularin, Wee1 inhibitor, osimertinib, JQ1, VE-822, and AZD6738 in high-risk patients. Furthermore, CCK-8 assays and Wright-Giemsa staining confirmed the crucial role of PARP1 in regulating MM cell viability. This PANoptosis-based prognostic model provides a valuable tool for predicting MM prognosis and guiding personalized treatment.
    Journal • Tumor mutational burden • PARP Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • LY96 (Lymphocyte Antigen 96)
    |
    Tagrisso (osimertinib) • cyclophosphamide • JQ-1 • berzosertib (M6620) • ceralasertib (AZD6738)
    9ms
    Molecular Profiling Reveals the Malignant Potential in Solid Pseudopapillary Neoplasms of the Pancreas. (PubMed, Cancer Lett)
    Tumor microenvironment analysis by using the GEO database, 850K methylation sequencing, NanoString transcriptome, highlighted enriched immune-suppressive stromal components in aggressive tumors. These findings establish a molecular signature linking methylation dysregulation, transcriptomic alterations, liquid biopsy, and immune evasion to SPN progression, offering potential biomarkers for risk stratification and therapeutic targeting.
    Journal
    |
    IFI16 (Interferon Gamma Inducible Protein 16) • LY96 (Lymphocyte Antigen 96)
    over1year
    Association of M2 macrophages with EMT in glioma identified through combination of multi-omics and machine learning. (PubMed, Heliyon)
    Our research underscores the efficacy of our model in predicting glioma prognosis and elucidates the connection between the M2 macrophages and EMT. Additionally, core genes such as LY96, C1QB, LGALS1, CSPG5, S100A8, and CHGB were identified as pivotal for mediating the occurrence of EMT induced by M2 macrophages.
    Journal • Tumor mutational burden • Machine learning
    |
    TMB (Tumor Mutational Burden) • LGALS1 (Galectin 1) • S100A8 (S100 Calcium Binding Protein A8) • C1QB (Complement C1q B Chain) • LY96 (Lymphocyte Antigen 96)
    almost2years
    Immunogenic cell death related mRNAs associated signature to predict immunotherapeutic response in osteosarcoma. (PubMed, Heliyon)
    The five-gene risk signature facilitate prognostic evaluation and prediction of osteosarcoma patients' response to immunotherapy. The risk signature also offered a possibility for the exploit of novel ICD-related treatment.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • TLR4 (Toll Like Receptor 4) • IFNGR1 (Interferon Gamma Receptor 1) • LY96 (Lymphocyte Antigen 96)
    almost2years
    The potential crosstalk genes and molecular mechanisms between glioblastoma and periodontitis. (PubMed, Sci Rep)
    FLI1 was identified as a potential key transcription factor (TF) regulating the three key crosstalk genes, with increased expression in the full dataset. These findings contribute to our understanding of the immune and inflammatory aspects of the comorbidity mechanism between GBM and PD.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • LY96 (Lymphocyte Antigen 96)
    almost2years
    A model based on immunogenic cell death-related genes predicts prognosis and response to immunotherapy in kidney renal clear cell carcinoma. (PubMed, Transl Cancer Res)
    This RM predicted patient prognosis and reflected the tumor IME of KIRC patients. Thus, this RM could be used to promote individualized treatments and provide potential novel targets for immunotherapy.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • TLR4 (Toll Like Receptor 4) • FOXP3 (Forkhead Box P3) • LY96 (Lymphocyte Antigen 96)
    2years
    Resistance to Combined Anthracycline-Taxane Chemotherapy Is Associated with Altered Metabolism and Inflammation in Breast Carcinomas. (PubMed, Int J Mol Sci)
    Furthermore, the amino acid transporter SLC7A5, distinguishing non-responders from responders, had significantly higher expression in tumors and metastases than in normal tissues (Kruskal-Wallis p = 8.2 × 10). The identified biomarkers underscore the significance of tumor metabolism and microenvironment in treatment resistance and can serve as a foundation for preclinical validation studies.
    Journal
    |
    LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • ANXA1 (Annexin A1) • SLC7A5 (Solute Carrier Family 7 Member 5) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • LY96 (Lymphocyte Antigen 96)
    2years
    Lessons of Nature in Trisomy-8 MDS and AML: Determinants of Clonal Drive (ASH 2023)
    8 itself. Indeed, we found transcriptomic changes pertinent to +8 MDS whose role in driving leukemogenesis and interaction with specific myeloid drivers needs to be confirmed by future experimentations on cellular and murine models.
    IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • STAG2 (Stromal Antigen 2) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • NSD3 (Nuclear Receptor Binding SET Domain Protein 3) • BAG4 (BAG Cochaperone 4) • PVT1 (Pvt1 Oncogene) • LY96 (Lymphocyte Antigen 96)
    |
    FLT3 mutation • DNMT3A mutation • RUNX1 mutation • U2AF1 mutation • STAG2 mutation